LANTHEUS HOLDINGS INC

NASDAQ: LNTH (Lantheus Holdings, Inc.)

Kemas kini terakhir: semalam, 1:32PM

59.89

1.34 (2.29%)

Penutupan Terdahulu 58.55
Buka 58.75
Jumlah Dagangan 354,385
Purata Dagangan (3B) 1,366,476
Modal Pasaran 4,072,169,728
Harga / Pendapatan (P/E TTM) 24.85
Harga / Pendapatan (P/E Ke hadapan) 9.38
Harga / Jualan (P/S) 2.46
Harga / Buku (P/B) 3.18
Julat 52 Minggu
47.25 (-21%) — 111.29 (85%)
Tarikh Pendapatan 6 Nov 2025
Margin Keuntungan 16.55%
Margin Operasi (TTM) 27.38%
EPS Cair (TTM) 3.51
Pertumbuhan Hasil Suku Tahunan (YOY) 0.80%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -44.30%
Jumlah Hutang/Ekuiti (D/E MRQ) 52.78%
Nisbah Semasa (MRQ) 5.74
Aliran Tunai Operasi (OCF TTM) 525.08 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 241.87 M
Pulangan Atas Aset (ROA TTM) 14.39%
Pulangan Atas Ekuiti (ROE TTM) 24.11%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Menaik Bercampur
Drug Manufacturers - Specialty & Generic (Global) Menaik Bercampur
Stok Lantheus Holdings, Inc. Menurun Menurun

AISkor Stockmoo

1.3
Konsensus Penganalisis 1.0
Aktiviti Orang Dalam NA
Volatiliti Harga 2.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal 2.0
Purata 1.25

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
LNTH 4 B - 24.85 3.18
KNSA 3 B - 90.20 6.03
ALVO 2 B - 22.70 -
BCRX 1 B - - 56.59
HROW 1 B - - 32.91
ETON 442 M - - 17.82

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 2.24%
% Dimiliki oleh Institusi 116.12%

Pemilikan

Nama Tarikh Syer Dipegang
Farallon Capital Management Llc 30 Sep 2025 3,477,227
Reinhart Partners, Llc. 30 Sep 2025 1,347,756
Julat 52 Minggu
47.25 (-21%) — 111.29 (85%)
Julat Harga Sasaran
61.00 (1%) — 84.00 (40%)
Tinggi 84.00 (B. Riley Securities, 40.26%) Beli
Median 78.50 (31.07%)
Rendah 61.00 (Truist Securities, 1.85%) Pegang
Purata 75.50 (26.06%)
Jumlah 2 Beli, 2 Pegang
Harga Purata @ Panggilan 51.99
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Truist Securities 10 Nov 2025 61.00 (1.85%) Pegang 50.69
Goldman Sachs 08 Oct 2025 77.00 (28.57%) Pegang 53.55
B. Riley Securities 16 Sep 2025 84.00 (40.26%) Beli 51.98
TD Cowen 15 Sep 2025 80.00 (33.58%) Beli 51.74

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
24 Nov 2025 Pengumuman Lantheus to Present Florbetaben F 18 Data at CTAD 2025
10 Nov 2025 Pengumuman Shareholders SueWallSt in New Class Action Against Lantheus Holdings, Inc. - Act Now
07 Nov 2025 Pengumuman Shareholders SueWallSt in New Class Action Against Lantheus Holdings, Inc. - Act Now
06 Nov 2025 Pengumuman Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update
06 Nov 2025 Pengumuman Lantheus Announces Leadership Transition Plan
04 Nov 2025 Pengumuman Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
03 Nov 2025 Pengumuman INVESTOR DEADLINE NEXT WEEK: RGRD LLP Announces that Lantheus Holdings, Inc. (LNTH) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
31 Oct 2025 Pengumuman Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
30 Oct 2025 Pengumuman Shareholders SueWallSt in New Class Action Against Lantheus Holdings, Inc. - Act Now
30 Oct 2025 Pengumuman Lantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
28 Oct 2025 Pengumuman Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease
27 Oct 2025 Pengumuman Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
23 Oct 2025 Pengumuman Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time
22 Oct 2025 Pengumuman Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
16 Oct 2025 Pengumuman Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
14 Oct 2025 Pengumuman LNTH INVESTOR ALERT: Lantheus Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD LLP
09 Oct 2025 Pengumuman Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
06 Oct 2025 Pengumuman Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
24 Sep 2025 Pengumuman Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan
19 Sep 2025 Pengumuman Shareholders SueWallSt in New Class Action Against Lantheus Holdings, Inc. - Act Now
12 Sep 2025 Pengumuman LNTH INVESTOR ALERT: Lantheus Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law
12 Sep 2025 Pengumuman Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
11 Sep 2025 Pengumuman Shareholders SueWallSt in New Class Action Against Lantheus Holdings, Inc. - Act Now
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda